Shanet Susan Alex

Ph.D. Pharmacy

Shanet Susan Alex, a medical writer, based in Kerala, India, is a Doctor of Pharmacy graduate from Kerala University of Health Sciences. Her academic background is in clinical pharmacy and research, and she is passionate about medical writing. Shanet has published papers in the International Journal of Medical Science and Current Research (IJMSCR), the International Journal of Pharmacy (IJP), and the International Journal of Medical Science and Applied Research (IJMSAR). Apart from work, she enjoys listening to music and watching movies.

Articles from Shanet

Mucosal COVID vaccine candidate powerfully protective in macaques

A recent research paper posted to the bioRxiv* preprint server illustrated the protective efficacy of the intranasal pediatric parainfluenza virus-vectored coronavirus disease 2019 (COVID-19) vaccine prospect, B/HPIV3/S-6P, in macaques.

26 May 2022

After SARS-CoV-2 infection, anti-chemokine antibodies correlate with better outcomes

A recent study posted to the bioRxiv* preprint server illustrated that specific chemokine antibodies aid in recognizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent individuals with a desirable disease course.

26 May 2022

A study on the safety of BNT162b2 COVID vaccine in children under five

In a recent research paper posted to the medRxiv* preprint server, scientists explored the safety of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 vaccine in children under five years of age.

25 May 2022

Association between reactogenicity and immunogenicity in SARS-CoV-2 mRNA-1273 vaccination

A recent study currently under review at Scientific Reports journal and posted to the Research Square* preprint server demonstrated a potential positive correlation between reactogenicity and immunogenicity of coronavirus disease 2019 (COVID-19) vaccination.

25 May 2022

The root causes of long-COVID still a mystery

In a recent article posted to the journal Annals of Internal Medicine, researchers presented baseline outcomes from a longitudinal assessment of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC), also known as long-COVID.

25 May 2022

Vaccinated individuals with SARS-CoV-2 infection develop virus-specific T cells inside their noses

In a recent study posted to the medRxiv* preprint server, investigators in Singapore showed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection elicited broadly specific virus-selective nasal resident CD8 and CD4 T cells.

24 May 2022